Why Acadia Pharmaceuticals Stock Is Soaring Today

Acadia Pharmaceuticals (ACAD) jumped 12.2% following a positive regulatory catalyst from Europe. The European Medicines Agency's Committee recommended approval of Daybue for treating Rett syndrome in the EU, marking a potential expansion for one of the company's two approved drugs.

Acadia focuses exclusively on rare neurological and psychiatric disorders, a niche where competition remains limited. The company has reached profitability, with its two commercialized therapies generating substantial revenue. Daybue, already approved in the U.S., treats Rett syndrome, a rare genetic neurological disorder that primarily affects females.

The European market opportunity for Rett syndrome treatment, while smaller than major therapeutic categories, represents incremental revenue in a space where Acadia faces minimal competitive pressure. The EMA Committee's recommendation typically precedes final approval from the European Commission.